Gastrointestinal

Gastroenterology

Prevalence

30.0 / 100K

38 drugs in development·24 companies·1 clinical trial

Drug Pipeline by Phase

Approved(7)

Drug	Company
afinitor	Novartis AG (NVS)
chlordiazepoxide	Amneal Pharmaceuticals, Inc. (AMRX)
diclofenac	Zomedica Corp. (ZOMDF)
everolimus	Mylan II B.V. (MYL)
hp+detect™	BIOMERICA INC (BMRA)
prednisone	DR REDDYS LABORATORIES LTD (RDY)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(7)

Drug	Company
bezuclastinib (CGT9486)	Cogent Biosciences, Inc. (COGT)
cgt9486	Cogent Biosciences, Inc. (COGT)
FOLFOX-4	IGM Biosciences, Inc. (IGMS)
FOLFOX-7	IGM Biosciences, Inc. (IGMS)
imu-381	IMMUNIC, INC. (IMUX)
Leucovorin Calcium	Arcus Biosciences, Inc. (RCUS)
Tumor vaccine-induced specific T-cell injection	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(5)

Drug	Company
Bezuclastinib	Cogent Biosciences, Inc. (COGT)
FOLFOX regimen	IGM Biosciences, Inc. (IGMS)
Leucovorin	Jazz Pharmaceuticals plc (JAZZ)
Lurbinectedin 4 MG Injection [Zepzelca]	Jazz Pharmaceuticals plc (JAZZ)
ompenaclid	IGM Biosciences, Inc. (IGMS)

Phase 1(9)

Drug	Company
arr-217	ArriVent BioPharma, Inc. (AVBP)
ARR-217 (MRG-007)	ArriVent BioPharma, Inc. (AVBP)
Domvanalimab	Arcus Biosciences, Inc. (RCUS)
hqp1351	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
idrx-42	GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
imatinib	Kura Oncology, Inc. (KURA)
Leucovorin	Arcus Biosciences, Inc. (RCUS)
modified folfirinox	AMGEN INC (AMGN)
rmc-6236	AMGEN INC (AMGN)

Preclinical(7)

Drug	Company
eq302	Equillium, Inc. (EQ)
eq504	Equillium, Inc. (EQ)
ngc-iri	Processa Pharmaceuticals, Inc. (PCSA)
pcs11t	Processa Pharmaceuticals, Inc. (PCSA)
pt001	Pandion Therapeutics, Inc. (PAND)
pt002	Pandion Therapeutics, Inc. (PAND)
vbx-100	RANGE IMPACT, INC. (RNGE)

Phase 1/Phase 2(2)

Drug	Company
dcc-3009	Deciphera Pharmaceuticals, Inc. (DCPH)
THE-630	Theseus Pharmaceuticals, Inc. (THRX)

Phase 4(1)

Drug	Company
XH001 injection	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 38 drugs in development for Gastrointestinal across 24 companies.

There are 1 clinical trial targeting Gastrointestinal tracked by BioSniper.

The estimated prevalence of Gastrointestinal is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.